[go: up one dir, main page]

PE20010205A1 - Derivados 3-sustituido de 2-carboxiciclopropil glicina como agonistas de glutamato - Google Patents

Derivados 3-sustituido de 2-carboxiciclopropil glicina como agonistas de glutamato

Info

Publication number
PE20010205A1
PE20010205A1 PE2000000525A PE0005252000A PE20010205A1 PE 20010205 A1 PE20010205 A1 PE 20010205A1 PE 2000000525 A PE2000000525 A PE 2000000525A PE 0005252000 A PE0005252000 A PE 0005252000A PE 20010205 A1 PE20010205 A1 PE 20010205A1
Authority
PE
Peru
Prior art keywords
carboxyclopropyl
glycine
alkyl
lil
substituted derivatives
Prior art date
Application number
PE2000000525A
Other languages
English (en)
Inventor
Tercero Maria Concepcion Pedregal
Cano Ivan Collado
Garcia Maria Rosario Gonzalez
Llorente Alicia Marcos
De Uralde Garmendia Beatriz Lopezz
Melendo Ana Belen Bueno
Original Assignee
Lilly Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Sa filed Critical Lilly Sa
Publication of PE20010205A1 publication Critical patent/PE20010205A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS 3-SUSTITUIDO DE 2-CARBOXICICLOPROPIL GLICINA DE FORMULA I, DONDE: R1 ES HALO-ALQUILO C1-C10, HALO-ALQUENILO C2-C10, (CH2)nY, SH, S(O)pR4, S(O)3H, NH2, NHR5, NR6R7, NHCOR8, NO2, CO2H, CONHR9, 1H-TETRAZO-5-LIL, 5-FENILTETRAZO-1-LIL, PO3H2; n ES 1-2, Y ES OH, CN, N3, OR3; R5, R6, R7, R8, R9 SON ALQUILO C1-C4, ARILO, ARIL-ALQUILO C1-C4, 1H-TETRAZO-5-LIL, CARBOXI-ALQUILO C1-C4, 1H-TETRAZO-5-LIL-ALQUILO C1-C4; p ES 0-3. SON COMPUESTOS PREFERIDOS (2SR, 1`SR, 2'SR, 3'SR)-2-[(3'(2''-HIDROXIETIL)-2'-CARBOXI)CICLOPROPIL]GLICINA, (2SR, 1RS, 2'RS, 3'RS)-2-[3'-MERCAPTOMETIL-2'-CARBOXICICLOPROPIL]GLICINA, (2S,1'S,2'R,3'R)-2-(3'-HIDROXIMETIL-2'-CARBOXICICLOPROPIL)GLICINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y A COMPUESTOS INTERMEDIOS. LOS COMPUESTOS I SON AGONISTAS DE GLUTAMATO EN LOS RECEPTORES METABOTROPICOS Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE DESORDENES DEL SISTEMA NERVIOSO CENTRAL COMO ENFERMEDADES NEUROLOGICAS, NEURODEGENERATIVAS
PE2000000525A 1999-06-03 2000-05-31 Derivados 3-sustituido de 2-carboxiciclopropil glicina como agonistas de glutamato PE20010205A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99500090 1999-06-03

Publications (1)

Publication Number Publication Date
PE20010205A1 true PE20010205A1 (es) 2001-03-16

Family

ID=8242502

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000525A PE20010205A1 (es) 1999-06-03 2000-05-31 Derivados 3-sustituido de 2-carboxiciclopropil glicina como agonistas de glutamato

Country Status (6)

Country Link
US (1) US6498180B1 (es)
EP (1) EP1189873A1 (es)
AU (1) AU5073600A (es)
CO (1) CO5180545A1 (es)
PE (1) PE20010205A1 (es)
WO (1) WO2000075101A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2849025B1 (fr) * 2002-12-20 2005-10-14 Rhodia Chimie Sa Esters d'allyle substitue par un groupe difluoromethylene, leur procede de synthese et leur utilisation
US7125871B2 (en) * 2000-05-31 2006-10-24 Eli Lilly And Company Excitatory amino acid receptor modulators
US7081481B2 (en) * 2000-05-31 2006-07-25 Eli Lilly And Company Excitatory amino acid receptor modulators
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CA2696948C (en) 2007-09-14 2013-04-30 Jose Maria Cid-Nunez 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
NZ584148A (en) * 2007-09-14 2011-05-27 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
EP2200985B1 (en) 2007-09-14 2011-07-13 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CN102143955B (zh) 2008-09-02 2013-08-14 Omj制药公司 作为代谢型谷氨酸受体调节剂的3-氮杂二环[3.1.0]己烷衍生物
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2552879T3 (es) 2010-11-08 2015-12-02 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2014117919A1 (en) * 2013-02-04 2014-08-07 Merck Patent Gmbh Positive allosteric modulators of mglur3
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EA033889B1 (ru) 2014-01-21 2019-12-05 Янссен Фармацевтика Нв Комбинация на основе лиганда sv2a и положительного аллостерического модулятора метаботропного глутаматергического рецептора 2 подтипа
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3481975B2 (ja) * 1992-09-08 2003-12-22 サントリー株式会社 （２ｓ，１’ｓ，２’ｒ）−２−（２−カルボキシ−３−置換オキシメチルシクロプロピル）グリシン及びその製造法
JPH08301825A (ja) 1995-03-07 1996-11-19 Suntory Ltd ３’−置換−（２−カルボキシシクロプロピル）グリシン
IT1276153B1 (it) 1995-11-17 1997-10-27 Roberto Pellicciari Derivati di glicina ad attivita' antagonista dei recettori metabotropi del glutammato
WO1998000391A1 (en) 1996-06-28 1998-01-08 Nippon Chemiphar Co., Ltd. Cyclopropylglycine derivatives and metabolic-regulation type l-glutamate receptor agonist
ES2131463B1 (es) 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.

Also Published As

Publication number Publication date
AU5073600A (en) 2000-12-28
WO2000075101A1 (en) 2000-12-14
US6498180B1 (en) 2002-12-24
CO5180545A1 (es) 2002-07-30
EP1189873A1 (en) 2002-03-27

Similar Documents

Publication Publication Date Title
PE20010205A1 (es) Derivados 3-sustituido de 2-carboxiciclopropil glicina como agonistas de glutamato
PE20040775A1 (es) DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2
CR7510A (es) DERIVADOS DE [1-4] DIAZEPINO[6,7,1-iJ)] QUINOLONA COMO AGENTES ANTIPSICOTICOS Y CONTRA LA OBESIDAD
ATE316076T1 (de) Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
CZ20032798A3 (cs) Nové pouzití slouceniny peptidové trídy pro lécbuallodynie nebo dalsích odlisných typu chronické nebo fantomové bolesti
PE20020911A1 (es) Derivados de indol como agonistas de 5ht2
ES2111650T3 (es) Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
CR6616A (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
BRPI0820112B8 (pt) derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
UY28144A1 (es) Agentes terapéuticos
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
LU92204I2 (fr) Dapoxetine sous toutes ses formes protégées par lebrevet de base
UY28376A1 (es) Agentes terapéuticos
CY1109734T1 (el) Ενωσεις για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας και/ή διαταραχων της ρυθμισης της γλυκοζης
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
RU94030812A (ru) Производные фосфоноянтарной кислоты, способ их получения и содержащие эти соединения фармацевтические композиции
BR0314488A (pt) Composto, composição farmacêutica e métodos de tratamento
ES2291454T3 (es) Utilizacion de carbamatos para prevenir o tratar trastornos del movimiento.
BR0311558A (pt) composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, métodos para afetar os receptores de glutamato metabotrópicos ligados a camp, para administrar uma quantidade eficaz de um composto e para tratar um distúrbio neurológico e psiquiátrico em um paciente, e, formulação farmacêutica
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
EA199900161A1 (ru) Производные пиридазино [4,5-в]-хинолин-5-оксида, их получение и применение в качестве антагонистов глицина
BR0311593A (pt) Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc
MX9301197A (es) Derivados de indol.
NO921000D0 (no) Hydrazonderivater, fremgangsmaate for fremstilling derav samt anvendelse derav

Legal Events

Date Code Title Description
FC Refusal